GHDX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the expense the company spent on research and development. Genomic Health, Inc.'s research and development for the three months ended in Dec. 2013 was $24.1 Mil. Its research and development for the trailing twelve months (TTM) ended in Dec. 2013 was $66.3 Mil.
This is the expense the company spent on research and development.
Genomic Health, Inc. Research & Development for the trailing twelve months (TTM) ended in Dec. 2013 was 13.663 (Mar. 2013 ) + 13.8 (Jun. 2013 ) + 14.726 (Sep. 2013 ) + 24.144 (Dec. 2013 ) = $66.3 Mil.
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Genomic Health, Inc. Annual Data
|Research & Development||10.0||9.5||12.8||22.1||28.6||35.7||33.2||39.9||49.1||66.3|
Genomic Health, Inc. Quarterly Data
|Research & Development||9.6||10.3||11.9||11.6||12.3||13.3||13.7||13.8||14.7||24.1|